The new breast cancer drugs palbociclib (Ibrance, Pfizer) and ribociclib (Kisqali, Novartis) should be routinely funded on the NHS, draft guidance from the National Institute for Health and Care...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jwyAVV
via
IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου